Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity

Immunology

Volumn 104, Issue 2, 2001, Pages 235-242

  Geba, Gregory P ^a   Ptak, Wlodzimierz ^b   Askenase, Philip W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN E; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CONTACT SENSITIVITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INHIBITION KINETICS; MALE; MAST CELL; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN SENSITIVITY; T LYMPHOCYTE;

ADMINISTRATION, CUTANEOUS; ANIMALS; CYCLOSPORINE; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; FEMALE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; PICRYL CHLORIDE; T-LYMPHOCYTES; TACROLIMUS;

EID: 0034772019     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01288.x     Document Type: Article

References (45)

1. Effector and regulatory molecules and mechanisms in delayed-type hypersensitivity (DTH)
2. An early component of delayed-type hypersensitivity mediated by T cells and mast cells
3. Serotonin initiation of delayed-type hypersensitivity: Mediation by a primitive Thy-1 + antigen-specific clone or by monoclonal IgE antibody
4. Delayed-type hypersensitivity in mast cell-deficient mice. Dependence on platelets for expression of contact sensitivity
5. Vascular endothelial cell expression of ICAM-1 and VCAM-1 at the onset of eliciting contact hypersensitivity in mice: Evidence for a dominant role of TNF-α
6. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment
7. T cells produce an antigen-binding factor with an in vivo activity analogous to IgE antibody
8. Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by T cell-derived antigen-binding factor
9. Delayed-type hypersensitivity (DTH) recruitment of T cell subsets via antigen-specific non IgE factors, and IgE antibodies: Relevance to asthma, autoimmunity and immune resistance to tumors and parasites
10. B-1 B cell IgM antibody initiates T cell elicitation of contact sensitivity
11. Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity and late T cell IFN-γ: A possible initiating role of B cells
12. A new paradigm of T cell allergy: Requirement for the B-1 cell subset
13. The effects of Cyclosporin A on the immune system
14. Cyclosporine: A new immunosupressive agent for organ transplantation
15. FK-506-a novel immunosupressant
16. Immunosuppressants at work
17. Cyclosporin A, FK-506 and rapamycin: Pharmacologic probes of lymphocyte activation
18. Biochemical characterization of the inhibitory effect of cyclosporin A on cytolytic T lymphocyte effector functions
19. Cyclosporin A inhibits rat mast cell activation
20. Cyclosporin A inhibits degranulation of rat basophilic leukemia cells and human basophils. Inhibition of mediator release without affecting PI hydrolysis or Ca 2+ fluxes
21. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin
22. Does cyclosporin A directly affect human Langerhans cell function?
23. Cyclosporin A inhibits the antigen-presenting function of freshly isolated human Langerhans cells in vitro
24. The effect of cyclosporin on epidermal cells. I. Cyclosporin inhibits accessory cell functions of epidermal Langerhans cells in vitro
25. The mechanism of action of cyclosporin A and FK-506
26. The mechanism of action of cyclosporin A and FK-506
27. Immunophilins in protein folding and immunosupression
28. Calcineurin is a common target of cyclophilin-cyclosporin A and FKB-FK-506 complexes
29. FK-506 and CsA-sensitive activation of the IL-2 promoter by calcineurin
30. FK-506 and cyclosporin, molecular probes for studying intracellular signal transduction
31. Cyclosporin A and FK-506 mediate differential effects on T cell activation in vivo
32. Differences between cyclosporin A and tacrolimus in organ transplantation
33. Monoclonal dinitrophenyl-specific murine IgE antibody. Preparation, isolation characterization
34. Tacrolimus is superior to cyclopsorine in liver transplantation
35. Delayed-type hypersensitivity is mediated by a sequence of two different T cell activities
36. + T cell populations that mediate delayed-type hypersensitivity
37. -) and CD3 negative; and expresses IL-3 receptors, but no IL-2 receptors
38. Delayed-type hypersensitivity initiation by early-acting cells that are antigen mismatched or MHC incompatible with late-acting, delayed-type hypersensitivity effector T cells
39. Human late asthmatic responses
40. Different mechanisms of release of vasoactive amines by mast cells occur in T cell-dependent compared to IgE-dependent cutaneous hypersensitivity responses
41. Absorption of topical tacrolimus (FK-506) in vitro through human skin: Comparison with Cyclosporin A
42. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
43. Effect of a new topical cyclosporin formulation on human allergic contact dermatitis
44. A randomized, vehicle controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children
45. Topical tacrolimus (FK-506): A new milestone in the treament of atopic dermatitis